Member Info for Balanced66

Yes they should be reported. Remember early on in another one of their bashing articles they quoted the wrong turnover - used part of the turnover as the whole year figure - that's unforgivable for a site that claims to champion the small investor.

Here's the Yahoo finance article which is taken from the MF website so it's our friends at the MF.

For once the "collective" has kicked in a balanced view is being given rather than the one sided negative bias we have seen to date.

Rate this as a "medium" term buy - I'll take that. Medium term is one which probably means a 2- 3 year view?

A positive article from them for once!

https://www.fool.co.uk/investing/2020/10/14/interested-in-the-novacyt-share-price-read-this-first/

This will only work imo if tests are done on site.

https://www.independent.co.uk/news/uk/politics/coronavirus-care-home-relatives-testing-visiting-winter-key-worker-b1012935.html

Less than 6 months to re-infection!

https://www.theguardian.com/world/2020/oct/13/man-25-catches-coronavirus-twice-in-first-such-us-case

Is this our test?

https://www.theguardian.com/business/2020/oct/12/goldman-sachs-to-offer-free-covid-19-tests-for-london-staff

Just ignore him/her.

Just opened an account today and posted on several different share boards the same message about wanting a lower entry, another Johnny come lately to the investment world it seems.

Focus on the business. If it is making progress and further progress then the share price will take care of itself.

Some consolidation is good to support further stronger rises.
Imv we are not overvalued but nothing goes up in a straight line.

Just my personal views.

The derampers are trying to get a lower entry. I've checked one the poster's history without naming him to give him attention and he is currently ramping Sar saying it is going to go to 2.5 by the weekend. So you have the same people who are rampers and derampers for their own purposes.

ShaunP

It was posted on Twitter.

I'll see if I can track down the post if someone doesn't beat me to it.

And then the "smaller" orders like the Hungary £5m and several hundred thousand pound orders are just trickling through all the time as well.

Thanks barchid.

Good points chester18.

Amati are excellent stock pickers - I got the idea for this stock by looking at their holdings and then analysing this stock. I share a number of holdings with Amati. Amati have also said they are VERY long-term with their holding timescales on the stocks they own.

There is a recent podcast which I have not listened to yet and apparently Amati make clear this is their favourite holding and the one they would hold for 10 years - when I get a chance to listen I'll confirm if they say anything different.

I'll have to read that later looks like a thorough analysis.

I used to have a negative view on placings but as Scoredagainsteps has highlighted nearly all the companies that have done one have usually go e on to make highs.

Here it is not to advance just one program but at least 3 purposes and Japan is mentioned so happy with it. I see it as accelerating progress which will bring more value medium to long term:

"Funds raised will be used primarily to support the continued development of the Company's third product, DITEST™ as well as commencing Phase III preparation activities for Chronocort® in the US and progressing the Group's early-stage pipeline."

Scoredagainsteps

Nothing like the mess that the other company made where we are both invested in.

Huge.

It is undervalued for a biotech. Actually making revenues in the millions but not making a fuss about things and just going about its day to day business.

aspers

Yes gdr share may go up based on how shares go up and down on aim due to speculation and you may therefore make money there.

Ncyt have more than delivered the goods.

However, with gdr they are likely to be loss making this financial year as well - they only have 2 months left this financial year and no deals or covid sales yet.

Before they can sell in the US or sell successfully they need FDA approval. Has this been obtained yet?

It should be the other way round Gdr people need to come here not go over there imv.

This company has delivered on its promises and more. It has imv always been a midcap company but constrained by financials. No longer the case.

Gdr has rarely delivered. Looks like this year will be another year of low single digit turnover. If they can't maximise income during Covid when will they?

I think of this as a goldmine - the gold is there and over time more and more of it will be produced from the mine.

It says a lot for the line up of the company's drugs. 2 out of 2 drugs - Alkindi and Chronocort passing phase 3 trials in succession. They also have Ditest so would people have confidence in that offering as also likely to be successful? I'd say yes. Also have pipeline of 2 other early stage products.

A lot of other biotechs have lots of different drug programs expecting a lot of failures and running the successful trials.

https://www.ft.com/content/aa48893b-9c90-4701-b317-67bda727bbda